fixed or mixed effects model [BE/BA News]

posted by BEQool  – 2024-09-10 09:35 (303 d 06:31 ago) – Posting: # 24196
Views: 7,422

Hello Helmut,

thank you for the answers.
I just wanted to point out that, if I understand correctly, in ICH M13A basically nothing changes (PE and 90%CI) compared to EMA guideline on how to perform an analysis when periods are missing (because subject is a fixed factor) but compared to FDA guideline (subject as a random factor) PE and 90% CI change a little because now subjects with missing periods have to be excluded from the analysis (and according to FDA guideline you shouldnt exclude them)?

❝ P.S.: I modified the script in such a way that you can specify the number of dropouts and subjects with missings. Try this:

❝    CV         <- 0.15

❝    theta0     <- 0.975

❝    target     <- 0.90

❝    alpha      <- 0.05

❝    per.effect <- 0

❝    carryover  <- c(0, 0)

❝    dropouts   <- 2

❝    missings   <- 1

❝ Interesting, isn’t it?


Thanks, interesting indeed :ok:

Regards
BEQool

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,682 registered users;
46 visitors (0 registered, 46 guests [including 11 identified bots]).
Forum time: 16:06 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5